Navigation Links
New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Date:8/5/2008

new Optimized Path Traversal feature, treatment times were further reduced with more efficient robotic motion.

"This new CyberKnife System configuration now allows us to deliver radiosurgical quality treatments almost as fast as radiation therapy," said Greg Spurlock, chief operating officer of US Radiosurgery, the managing partner of Oklahoma CyberKnife, LLC. "With the CyberKnife System however, the entire course of therapy is completed in one to five treatments. Compared to the two month regimen of 30 to 40 treatments required with conventional radiation therapy, the CyberKnife System clearly benefits both the patient and the provider."

Lung cancer treatments with the CyberKnife System are typically completed in three sessions. The net result of the introduction of these new technologies is to deliver an entire course of radiosurgery in about 1.5 hours. The shorter treatment regimen of CyberKnife radiosurgery not only improves patients' quality of life by not requiring a prolonged course of daily treatment visits, it can also lighten the burden on healthcare providers, saving time, expense and overhead, while also providing for significantly greater patient throughput.

"For all radiation delivery systems, plan quality and treatment time have historically had an inverse relationship," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "While other radiosurgery systems actively promote fast treatment times, plan quality often suffers accordingly. Integrating all of the latest technologies, CyberKnife treatment times can now be reduced considerably with absolutely no sacrifice in treatment quality."

While Oklahoma CyberKnife, LLC purchased its CyberKnife System with all the next generation upgrades included, those same upgrades were made available to existing customers through Accuray's Diamond Elite Service Agreement, which enables customers to choose the right upgrades and payment plans to
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...PRNewswire/--Reportlinker.comannouncesthatanewmark...HolterMonitoringSystems-AGlobalMarketReview ,,...itoring-Systems---A-Global-Market-Review.html#utm_...gn=prnewswire ,, Cardiovascularmonitoringis...ientsneedtobecontinuouslymonitoredduringdiagnostic...
(Date:11/23/2009)...andNOIDA,India,Nov.23/PRNewswire-USNewswire/--Jubi...AB),andSouthernResearchInstitutetodayannouncedajoi...nnovationandenablingtechnologiesintheareasofOncolo...ueU.S.-Indiaarbitragedandleveragedpartnershipthatw...rpatientsworldwide.AMemorandumofUnderstandingwassi...
(Date:11/23/2009)...,Nov.23/PRNewswire-FirstCall/-- CumberlandPharmace...-lineresultsfromastudyevaluatingthesafetyandeffica...nhospitalizedburnpatients. ,, Statisticalsignif...verinburnpatientsoverthefirst24hoursoftreatment.Th...ddegreeburnscoveringmorethan10percenttotalbodysurf...
Breaking Medicine Technology:Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3Exercise May Prevent Prostate Cancer 3A Study 58366 1BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease 58361 1BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease 58361 2Comprehensive understanding of bacteria could lead to new insights into many organisms 10114 1Comprehensive understanding of bacteria could lead to new insights into many organisms 10114 2
(Date:11/24/2009)...sts offer advice on the topic of most concern to M...mpletely and finally; forsake utterly; to desert. ...s) November 24, 2009 -- Dr. Suzanne LaCombe and Dr...is its groundbreaking "The New Paradigm for 2... ( http://www.myshrink.com )., , ,Titled "Aba...
(Date:11/24/2009)...hes EyeCentral Remote Video Platform for the Secur... for Central Stations and Security Dealers. , ...r 24, 2009 -- NCL Security Launches EyeCentral Rem...nerate Recurring Monthly Revenue for Central Stati...urity systems has been and still is a great trend ...
(Date:11/23/2009)...n determined that only 663,000 of the approximatel...V) infection received antiviral therapy between 20...ng, in part because only half of the patients know...inues, by 2030 less than 15% of liver-related deat.... This study, the first to analyze nationwide pra...
(Date:11/23/2009)...gh cost of drug advertising that does little to bo...rsity of British Columbia health policy researcher... of Internal Medicine , examined the US sales patt... by the trade name Plavix used to prevent blood cl...ected to study the impact of advertising on sales ...
(Date:11/23/2009)...the problem, researchers say , , MONDAY,...ir anger over unfair treatment at work could be hu... , Men who consistently failed to express their... supervisor were more than twice as likely to have...ho vented their anger, claims a report in the Nov....
Breaking Medicine News(10 mins):Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3
...ions seen on MRIs with limited side effects, study...) -- One of the first pills to treat the "relapse-...wn to help fight the disease with few side effects... large, this doesn,t look as strong as the stronge...
...rigo Company,(Nasdaq: PRGO ; TASE) today announce.... Food and Drug Administration to manufacture and ...mg/mL. The product is comparable,to McNeil Consume...Joseph C. Papa stated, "This approval,reflects bot...
...ir shows no added benefit , , THURSDAY, Ju...r (Zovirax) doesn,t reduce the risk of HIV-1 infec... genital herpes, a U.S. study finds. , Previous re...on by two- to threefold. , In this new, randomized...
...x Competitive Bidding System for DMEPOS,Equipment,..., chair of the House Ways & Means Health Subcommit...MEPOS Competitive Acquisition Reform,Act of 2008. ...ill. In response, Bruce T. Roberts, RPh, executive...
...ternational clinical trial coordinated by the Mont...ew England Journal of Medicine . The Atrial Fibril... was a prospective, multicentre project involving ... (a very common heart rhythm disorder) further inc...
...19 /Xinhua-PRNewswire-FirstCall/ -- Benda,Pharmace...ased,pharmaceutical company producing both Gendici...the treatment of cancer, and traditional Chinese a...008. Mr. Mo joined the Board in 2007 and served as...
Other Medicine News:Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3Health News:Benda Pharmaceutical Announces Resignation of Board Member 2
Refraction System RT-2100
Ultramatic RX Master PHOROPTOR Refracting Instrument - Plus Cylinder Black
Maddox Rod, short handle (12cm)
Snellen 10' Eye Test Chart
Medicine Products: